Abstracts Archive - Page 580 of 2607 - ACR Meeting Abstracts

Abstract Number: 1455 • ACR Convergence 2022
Immune Thrombocytopenic Purpura and Subsequent Development of Systemic Lupus Erythematosus
Gelsomina Alle¹, Marina Scolnik¹, VALERIA SCAGLIONI¹, John Fredy Jaramillo Gallego¹, Mayra Alejandra Tobar Jaramillo¹, Rodolfo Alvarado¹, Enrique R Soriano² and Javier Eduardo Rosa¹, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The aim of this study is to assess the incidence of Systemic Lupus Erythematosus (SLE) in a cohort of patients with Immune Thrombocytopenic Purpura…
Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Lifan Zhang¹, xiaoqing zou², Lantian Xie³, Jianghao Liu³, zhengrong yang⁴, qifei cao⁴, Chunlei Li⁵, Xiaochuan Sun⁵, Fengchun ZHANG⁶, Yan Zhao⁷, Xiaofeng Zeng⁸ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Beijing, China, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…
Abstract Number: 1461 • ACR Convergence 2022
The Frequency of Systemic Lupus Erythematosus in Patients with Immune Thrombocytopenic Purpura: A Systematic Meta-analysis
Omer Pamuk¹ and Sarfaraz Hasni², ¹NIH/NIAMS, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: Immune thrombocytopenic purpura (ITP) is an organ-specific autoimmune disease and its etiopathogenetic mechanisms are suggestive of systemic autoimmune diseases (SAD) such as systemic lupus…
Abstract Number: 1462 • ACR Convergence 2022
Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis
Samar Soliman¹, Samantha Stanley², Kamala Vanarsa², Faten Ismail³, Chi Chiu Mok⁴ and Chandra mohan⁵, ¹Rheumatology Department, Faculty of Medicine, Minia university, Minya, Egypt, ²Department of Biomedical Engineering, University of Houston, Houston, TX, ³Department of Rheumatology, Faculty of Medicine, Minia University, Minia, Egypt, ⁴Tuen Mun Hospital, Hong Kong, China, ⁵University of Houston, Houston, TX
Background/Purpose: The goal of this exploratory study is to determine if urine:serum fractional excretion ratios can outperform the corresponding urinary biomarker proteins in identifying active…
Abstract Number: 1452 • ACR Convergence 2022
Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis
James Sullivan¹ and Emily Littlejohn², ¹Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Long-term glucocorticoid use can lead to adverse outcomes independent of SLE disease activity. Identifying factors associated with long-term glucocorticoids is an important step towards…
Abstract Number: 1460 • ACR Convergence 2022
Neuropsychiatric Lupus in Late and Early Onset Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-analysis
Omer Pamuk¹, Saja Ali² and Sarfaraz Hasni², ¹NIH/NIAMS, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: The diagnosis of neuropsychiatric lupus (NPSLE) is challenging due to its variegated presentation, absence of diagnostic biomarkers and radiological imaging. The NPSLE is further…
Abstract Number: 1473 • ACR Convergence 2022
Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
Jack Zent¹, Kristy Bell², Brooke Williams², Prathyusha Bachali³ and Peter Lipsky⁴, ¹AMPEL BioSolutions LLC, Leesburg, VA, ²AMPEL BioSolutions LLC, Charlottesville, VA, ³AMPEL BioSolutions, Redmond, WA, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical presentations. Patient-reported outcomes (PROs) can aid in the measurement of the burden of…
Abstract Number: 1467 • ACR Convergence 2022
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience
Savino Sciascia¹, Alice Barinotti², Massimo Radin², Irene Cecchi¹, Elisa Menegatti², Vittorio Modena², Daniela Rossi², Simone Baldovino², Roberta Fenoglio² and Dario Roccatello², ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy
Background/Purpose: Lupus Nephritis (LN) is a major cause of mortality/morbidity in patients affected by Systemic Lupus Erythematosus (SLE). Reliable prognostic markers, especially related to the…
Abstract Number: 1469 • ACR Convergence 2022
Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Caroline Spitznagel, Fedelis Mutiso, Jim Oates and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher prevalence and incidence of herpes zoster (HZ) compared with the general population. Our study was…
Abstract Number: 1465 • ACR Convergence 2022
Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort
Vineeta Shobha¹, Liza Rajasekhar², Sandra Manuel¹, Chengappa Kavadichanda³, Ashish J Mathew⁴, Ranjan Gupta⁵, Manish Rathi⁶, Parasar Ghosh⁷, Saumya Ranjan Tripathy⁸, Avinash Jain⁹ and Amita Aggarwal¹⁰, ¹St. John’s Medical College Hospital, Bangalore, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³JIPMER, Pondicherry, Puducherry, India, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵All India Institute of Medical Sciences, New Delhi, India, ⁶PGIMER Chandigarh, Chandigarh, India, ⁷Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁸SCB medical college, Cuttack, India, ⁹SMS Medical College, Lucknow, India, ¹⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Antiphospholipid Antibody (aPL) are described in 11-40% of patients with SLE. Whether the presence of any of the aPLs or combinations thereof, can accurately…
Abstract Number: 1476 • ACR Convergence 2022
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
Rosa Arvizu-Rivera¹, jiram torres-Ruiz², Alfredo Pérez-Fragoso², Beatriz Alcalá-Carmona³, Miroslava Nuñez-Aguirre⁴, Ana Sofía Vargas-Castro⁴, Abdiel Absalón-Aguilar³, Jaquelin Lira-Luna⁴ and Diana Gómez-Martín², ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, ²INCMNSZ, Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico
Background/Purpose: Enhanced netosis has been acknowledged as pathogenic in Systemic Lupus Erythematosus (SLE). The presence of antibodies against neutrophil extracellular traps (anti-NETs) in patients with…
Abstract Number: 1475 • ACR Convergence 2022
Epidemiology of Acute Ischemic Stroke in Patients with Systemic Lupus Erythematosus
Uzair Khan¹, Izza Bazigh², Achint Patel³, Aaparna Singh³, Neha Ghalib³, Ghazi Farman⁴, Salman Muddassir³, Farrukh Zaidi⁵, Sami Mughni³ and Adam Grunbaum⁶, ¹HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Odessa, FL, ²HCA Florida Oak Hill Hospital, Spring Hill, FL, ³HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Spring Hill, FL, ⁴Rehman Medical College, Spring Hill, FL, ⁵HCA Healthcare Florida / USF Morsani College of Medicine GME Consortium / Oak Hill Hospital, Port Richey, FL, ⁶Gulf Coast Rheumatology, Trinity, FL
Background/Purpose: Vascular events, including cerebrovascular accidents (CVA) occur earlier and more frequently in patients with Systemic Lupus Erythematosus (SLE) compared with healthy individuals. Several studies…
Abstract Number: 1477 • ACR Convergence 2022
Prevalence and Risk Factors of Fragility Fractures in Systemic Lupus Erythematosus: A Longitudinal Study over 12 Years
Chi Chiu Mok¹, Kar Li Chan², Ling Yin Ho³ and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Tsing Yi, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong SAR, China, ⁴Hospital Authority, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence and risk factors of fragility fractures in a longitudinal cohort of patients with SLE.Methods: All patients who fulfilled ≥4 1997…
Abstract Number: 1418 • ACR Convergence 2022
Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
Colleen Correll¹, Scott Stryker², David Collier³, Anne Dennos⁴, Stephen Balevic⁵, Thomas Phillips⁵ and Tim Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Amgen Inc., San Francisco, CA, ³Amgen Inc., Simi Valley, CA, ⁴Duke University, Durham, NC, ⁵Duke Clinical Research Institute, Durham, NC, ⁶Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL
Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important…
Abstract Number: 1368 • ACR Convergence 2022
How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey
Ivan Foeldvari¹, Nicola Helmus² and Suzanne Li³, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ³Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ
Background/Purpose: Pediatric scleroderma consists of two diseases, juvenile localized scleroderma (jLS) and juvenile systemic sclerosis (jSSc). While jLS and jSSc share some disease processes, there…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].